Activation of the mTOR pathway by low levels of xenoestrogens in breast epithelial cells from high-risk women

Carcinogenesis

Volumn 32, Issue 11, 2011, Pages 1724-1733

  Goodson, William H ^a   Luciani, Maria Gloria ^a   Sayeed, S Aejaz ^a,b   Jaffee, Ian M ^a   Moore, Dan H ^a,c   Dairkee, Shanaz H ^a  

^a CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4,4' ISOPROPYLIDENEDIPHENOL; ESTROGEN; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE B; RAPAMYCIN; REACTIVE OXYGEN METABOLITE; TAMOXIFEN; XENOBIOTIC AGENT;

APOPTOSIS; ARTICLE; BREAST CANCER; BREAST EPITHELIUM; CANCER INCIDENCE; CONTROLLED STUDY; ENZYME ACTIVATION; GENE EXPRESSION; HIGH RISK POPULATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; BLOTTING, WESTERN; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CELL PROLIFERATION; CELLS, CULTURED; ESTROGENS, NON-STEROIDAL; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MIDDLE AGED; PHENOLS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; REACTIVE OXYGEN SPECIES; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; TOR SERINE-THREONINE KINASES;

EID: 80755144021     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgr196     Document Type: Article

References (67)

1. Vom Saal, F.S. et al. (2005) An extensive new literature concerning lowdoes effects of bisphenol-A shows the need for a new risk assessment. Environ. Health Perspec., 113, 926-933.
2. Darbre, P.D. et al. (2008) Paraben esters: review of recent studies of endocrine toxicity, absorption, esterase and human exposure, and discussion of potential human risks. J. Appl. Toxicol., 28, 561-578.
3. Calafat, A.M. et al. (2008) Exposure of the U.S. population to bisphenol A and 4-tertiary-octylphenol: 2003-2004. Environ. Health Perspect., 116, 39-44.
4. Statistics Canada. Bisphenol A concentrations in the Canadian population, 2007 to 2009. http://www.statcan.gc.ca/pub/82-003-x/2010003/article/11324/tbl/tbl1-eng.htm (17 April 2011, date last accessed).
5. Padmanabhan, V. et al. (2008) Maternal bisphenol-A levels at delivery: a looming problem? J. Perinatol., 28, 258-263.
6. Schonfelder, G. et al. (2002) Parent bisphenol A accumulation in the maternal-fetal-placental unit. Environ. Health Perspect., 110, A703-A707.
7. Zhang, J. et al. (2011) GC-MS analysis of bisphenol A in human placental and fetal liver samples. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 879, 209-214.
8. Sun, Y. et al. (2004) Determination of bisphenol A in human breast milk by HPLC with column-switching and fluorescence detection. Biomed. Chromotogr., 18, 501-507.
9. Hiroi, H. et al. (1999) Differential interactions of bisphenol A and 17 betaestradiol with estrogen receptor alpha and ER-beta. Endocr. J., 46, 773-778.
10. Matthews, J.B. et al. (2011) In vitro and in vivo interactions of bisphenol A and its metabolite, bisphenol A glucuronide, with estrogen receptors α and ß. Chem. Res. Toxicol., 14, 149-157.
11. Lewis, J.B. et al. (2000) 4-Hydroxytamoxifen-induced cytotoxicity and bisphenol A: competition for estrogen receptors in human breast cancer cell lines. In Vitro Cell. Dev. Biol. Anim., 36, 320-326.
12. LaPensee, E.W. et al. (2009) Bisphenol-A at low nanomolar does confers chemoresistance in estrogen receptor alpha positive and negative breast cancer cells. Environ. Health Perspect., 117, 175-180.
13. Jenkins, S. et al. (2009) Oral exposure to bisphenol A increases dimethylbenzanthracene-induced mammary cancer in rats. Environ. Health Perspect., 117, 910-915.
14. Markey, C.M. et al. (2001) In utero exposure to bisphenol A alters the development and tissue organization of the mouse mammary gland. Biol. Reprod., 65, 1215-1223.
15. Masuno, H. et al. (2005) Bisphenol A accelerates terminal differentiation of 3T3-L1 cells into adipocytes through the phosphatidylinositol 3-kinase pathway. Toxicol. Sci., 84, 319-327.
16. Bontempo, P. et al. (2009) Molecular analysis of the apoptotic effects of BPA in acute myeloid leukemia cells. J. Transl. Med., 18, 48.
17. Darbre, P.D. et al. (2004) Concentrations of parabens in human breast tumors. J. Appl. Toxicol., 24, 5-13.
18. Byford, J.R. et al. (2002) Oestrogenic activity of parabens in MCF7 human breast cancer cells. J. Steroid Biochem. Mol. Biol., 80, 49-60.
19. Pugazhendhi, D. et al. (2007) Comparison of the global gene expression profiles produced by methylparaben, n-butylparaben, and 17-beta estradiol in MCF7 human breast cancer cells. J. Appl. Toxicol., 27, 67-77.
20. Ravdin, P.M. et al. (2007) The decrease in breast-cancer incidence in 2003 in the United States. N. Engl. J. Med., 356, 1670-1673.
21. Jungheim, E.S. et al. (2011) Short-term use of unopposed estrogen. A balance of inferred risks and benefits. JAMA, 305, 1354-1355.
22. Dey, S. et al. (2009) Xenestrogens may be the cause of high and increasing rates of hormone receptor positive breast cancer in the world. Med. Hypotheses, 72, 652-656.
23. Anderson, W.F. et al. (2010) Male breast cancer: a population-based comparison with female breast cancer. J. Clin. Oncol., 28, 232-239.
24. Dairkee, S.H. et al. (2008) Bisphenol A induces a profile of tumor aggressiveness in high-risk cells from breast cancer patients. Cancer Res., 68, 2076-2080.
25. Hay, N. et al. (2004) Upstream and downstream of mTOR. Genes Dev., 18, 1926-1945.
26. Strimpakos, A.S. et al. (2009) The role of mTOR in the management of solid tumors. Cancer Treat. Rev., 35, 148-159.
27. Ginsberg, G. et al. (2009) Does rapid metabolism ensure negligible risk from bisphenol A? Environ. Health Perspect., 117, 1639-1643.
28. Hengstler, J.G. et al. (2011) Critical evaluation of key evidence on the human health hazards of exposure to bisphenol A. Crit. Rev. Toxicol., 41, 263-291.
29. Armengol, G. et al. (2007) 4E-binding protein 1: a key molecular "Funnel Factor" in human cancer with clinical implications. Cancer Res., 67, 7551-7555.
30. Ursin, G. et al. (2003) Mammographic density and breast cancer in three ethnic groups. Cancer Epidemiol Biomarkers Prev., 12, 332-338.
31. Dairkee, S.H. et al. (2007) Oxidative stress pathways are highlighted in an immortalization signature in breast cancer. Oncogene, 26, 6269-6279.
32. Shoker, B.S. et al. (1999) Oestrogen receptor expression in the normal and pre-cancerous breast. J. Pathol., 188, 237-244.
33. Warner, M. et al. (2000) The normal and malignant mammary gland: a fresh look with ERß on board. J. Mammary Gland Biol. Neoplasia, 5, 289-294.
34. Shaaban, A.M. et al. (2003) Declining estrogen receptor-ß expression defines malignant progression of human breast neoplasia. Am. J. Surg. Pathol., 27, 1502-1512.
35. Fisher, B. et al. (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant breast and Bowel Project P-1 study. J. Natl. Cancer Inst., 90, 1371-1388.
36. Poweles, T.J. et al. (2007) Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J. Natl. Cancer Inst., 99, 283-290.
37. Baker, J.C. et al. (2008) ESR1 promoter hypermethylation does not predict atypia in RPFNA nor persistent atypia after 12 months of tamoxifen. Cancer Epidemiol. Biomarkers Prev., 17, 1884-1890.
38. Debnath, J. et al. (2002) The role of apoptosis in creating and maintaining luminal space within normal and oncogene-expressing mammary acini. Cell, 111, 29-40.
39. Galbaugh, T. et al. (2006) EGF-induced activation of Akt results in mTORdependent p70S6 kinase phosphorylation and inhibition of HC11 cell lactogenic differentiation. BMC Cell Biol., 7, 34.
40. Kim, S.H. et al. (2009) Proteomic and phosphoproteomic alterations in benign, premalignant and tumor human breast epithelial cells and xenograft lesions: biomarkers of progression. Int. J. Cancer, 124, 2813-2828.
41. Zhou, X. et al. (2004) Activation of the Akt/mammalian target of rapamycin/ 4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers. Clin. Cancer Res., 10, 6779-6788.
42. Perezz-Tenorio, G. et al. (2002) Activation of SKT/PBK in breast cancer predicts a worse outcome among endocrine treated patients. Br. J. Cancer, 86, s40-S45.
43. Kirkegaard, T. et al. (2005) AKT activation predicts outcome in breast cancer patients treated with tamoxifen. J. Pathol., 207, 139-146.
44. De Vivo, I. et al. (2000) Novel germline mutations in the PTEN tumour suppressor gene found in women with multiple cancers. J. Med. Genet., 37, 336-341.
45. Agrawal, S. et al. (2006) Differential expression of novel naturally occurring splice variants of PTEN and their functional consequences in Cowden syndrome and sporadic breast cancer. Hum. Mol. Genet., 15, 777-787.
46. Rojo, F. et al. (2007) 4E-binding protein 1, a cell signaling hallmark in breast cancer that correlates with pathologic grade and prognosis. Clin. Cancer Res., 13, 81-89.
47. Noh, W.C. et al. (2004) Determinants of rapamycin sensitivity in breast cancer cells. Clin. Cancer Res., 10, 1013-1023.
48. Price, D.J. et al. (1992) Rapamycin-induced inhibition of the 70-kilodalton S6 protein kinase. Science, 257, 973-977.
49. Baselga, J. et al. (2009) Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J. Clin. Oncol., 27, 2630-2637.
50. Macaskil, E.J. et al. (2011) The mammalian target of rapamycin inhibitor everolimus (RAD001) in early breast cancer: results of a pre-operative study. Breast Cancer Res. Treat., 128, 725-734.
51. Hanahan, D. et al. (2011) Hallmarks of cancer: the next generation. Cell, 144, 646-674.
52. Buchholz, T.A. et al. (2003) Chemotherapy-induced apoptosis and Bcl-2 levels correlate with breast cancer response to chemotherapy. Cancer J., 9, 33-41.
53. Davis, D.W. et al. (2003) Automated quantification of apoptosis after neoadjuvant chemotherapy for breast cancer: early assessment predicts clinical response. Clin. Cancer Res., 9, 955-960.
54. Ellis, P.A. et al. (1997) Induction of apoptosis by tamoxifen and ICI 182780 in primary breast cancer. Int. J. Cancer, 72, 608-613.
55. Kallio, A. et al. (2005) Role of mitochondria in tamoxifen-induced rapid cell death of MCF-7 breast cancer cells. Apoptosis, 10, 1395-1410.
56. Eriksson, D. et al. (2010) Radiation-induced cell death mechanisms. Tumour Biol., 31, 363-372.
57. Goodson, W.H.3rd et al. (1997) The prognostic value of proliferation indices: a study with in vivo bromodeoxyuridine and Ki-67. Breast Cancer Res. Treat., 59, 113-123.
58. Ellis, M.J. et al. (2008) Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J. Natl. Cancer Inst., 100, 1380-1388.
59. deLima, G.R. et al. (2003) Effects of low dose tamoxifen on normal breast tissue from premenopausal women. Eur. J. Cancer, 39, 891-898.
60. Bundred, N.J. et al. (2002) Fulvestrant, an estrogen receptor downregulator, reduces cell turnover index more effectively than tamoxifen. Anticancer Res., 22, 2317-2320.
61. Sun, H. et al. (2011) Co-administration of perifosine with paclitaxel synergistically induces apoptosis in ovarian cancer cells: more than just AKT inhibition. Cancer Lett, 310, 118-128.
62. Pastor, M.D. et al. (2009) mTOR/S6 kinase pathway contributes to astrocyte survival during ischemia. J. Biol. Chem., 284, 22067-22078.
63. Storz, P. (2005) Reactive oxygen species in tumor progression. Front. Biosci., 10, 1881-1896.
64. Liou, G.Y. et al. (2010) Reactive oxygen species in cancer. Free Radic. Res., 44, 479-496.
65. Nazarawicz, R.R. et al. (2007) Tamoxifen induces oxidative stress and mitochondrial apoptosis via stimulating mitochondrial nitric oxide synthesis. Cancer Res., 67, 1282-1290.
66. Ramanathan, B. et al. (2005) Resistance to paclitaxel in proportional to cellular total antioxidant capacity. Cancer Res., 65, 8455-8460.
67. Diehn, M. et al. (2009) Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature, 458, 780-785.